- Home
- CEE vs OTLK Comparison
CEE vs OTLK Comparison
Compare CEE & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CEE | OTLK |
|---|---|---|
| Founded | 1990 | 2010 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.1M | 96.4M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | CEE | OTLK |
|---|---|---|
| Price | $17.75 | $1.81 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.67 |
| AVG Volume (30 Days) | 22.0K | ★ 3.1M |
| Earning Date | 01-01-0001 | 12-19-2025 |
| Dividend Yield | ★ 3.86% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,413,535.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $343.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.80 | $0.79 |
| 52 Week High | $10.32 | $3.39 |
Technical Indicators
Market Signals| Indicator | CEE | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 68.71 | 47.18 |
| Support Level | $16.90 | $1.77 |
| Resistance Level | $17.34 | $2.54 |
| Average True Range (ATR) | 0.52 | 0.22 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 82.12 | 17.34 |
Price Performance
Historical ComparisonAbout CEE The Central and Eastern Europe Fund Inc. (The)
CENTRAL & EASTERN EUROPE FUND, INC. is a closed-end management investment company. The Fund's objective is to seek long-term capital appreciation. It invests in the equity or equity-linked securities of issuers domiciled in Central and Eastern Europe.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.